Adjuvant Chemotherapy of Breast Cancer

To the Editor: Dr. Stephen Carter's timely editorial on adjuvant chemotherapy of breast cancer 1 may leave many readers in limbo with regard to three issues. First of all, should a no-treatment control be required in most surgical adjuvant studies? Secondly, is systemic chemohormonal therapy warranted in high-risk patients with negative lymph nodes? Thirdly, is breast cancer curable by chemotherapy? Dr. Carter lists as an important criterion a "surgery only" control group like those used in the National Surgical Adjuvant Breast Study Project and Milan trials begun in 1972 and 1973. This feature should no longer be a requirement, since it . . . No extract is available for articles shorter than 400 words.